**Author details**

Yang Wang<sup>1</sup> and Lingxiang Liu<sup>2</sup> \*

\*Address all correspondence to: llxlau@163.com

1 Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China

vivo antitumor activity of su11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clinical Cancer Research : An Official

Target Therapy for Kidney Cancer

149

http://dx.doi.org/10.5772/intechopen.73386

[7] Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM. Mint: Randomized phase ii trial of firstline treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clini-

[8] Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM. Mint: Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase iii treatment approaches in renal cancer global evaluation trial. Journal of Clinical Oncology : Official Journal of the American

Society of Clinical Oncology. 2009;**27**:3312-3318. DOI: 10.1200/JCO.2008.19.5511

[9] Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM. Mint: Sorafenib in advanced clear-cell renal-cell carcinoma. New England Journal of Medicine. 2007;**356**:125-134. DOI: 10.1056/NEJMoa060655

[10] Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, DR L, Hariharan S, Motzer RJ. Mint: Randomized phase iii trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American

[11] Haas NBMJ, Uzzo RG, Atkins MB, Wilding G, Pins M, et al. Mint: Initial results from assure (e2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ecog-acrin-led,

[12] Procopio G, Grassi P, Cognetti F, Milella M, Mosca A, Chiuri VE, et al. A randomized, opne label, multicenter phase 2 study to evaluate the efficacy of sorafenib in patients (pts) with advanced renal cell carcinoma (rcc) after radical resection of metastases: Resort trial.

[13] Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Mint: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England Journal of

[14] Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Mint: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of

Society of Clinical Oncology. 2014;**32**:760-767. DOI: 10.1200/JCO.2013.50.3961

nctn phase iii trial. Journal of Clinical Oncology. 2015;**33** (suppl 7; abstr 403)

Journal of Clinical Oncology. 2016;**34** (suppl; abstr tps4582)

Medicine. 2007;**356**:115-124. DOI: 10.1056/NEJMoa065044

Clinical Oncology. 2009;**27**:3584-3590. DOI: 10.1200/JCO.2008.20.1293

Journal of the American Association for Cancer Research. 2003;**9**:327-337

cal Oncology. 2009;**27**:1280-1289. DOI: 10.1200/jco.2008.19.3342

2 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
